Tagged as: Chime Biologics

Recent Biosimilar Commercialization Developments

Insulin Biosimilars: Meitheal Pharmaceuticals, Inc. has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceuticals Co., Ltd. to commercialize Tonghua Dongbao’s three insulin biosimilars (insulin aspart, insulin lispro, and insulin glargine) in the U.S. market.  Meitheal and Tonghua Dongbao will be jointly responsible for development and supply, with the expectation…

Read More